Arrowhead Reports Positive Phase 2a Trial Results For Patients With Hepatitis B
September 24, 2015 at 19:37 PM EDT
Shares of Arrowhead surged 21% after announcing positive phase 2a trial results for its Hepatitis B drug ARC-520.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |